NCT04736134View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions
Healthy Participants
Interventions
BIOLOGICAL

BMS-986326

Specified dose on specified days

OTHER

Placebo matching BMS-986326

Specified dose on specified days

BIOLOGICAL

Multiple Ascending Dose SC

Specified dose on specified days

OTHER

Multiple Ascending Dose Placebo

Specified dose on specified days

Trial Locations (1)

10117

Local Institution - 0001, Berlin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04736134 - A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants | Biotech Hunter | Biotech Hunter